🚀
Enjoy a 7-Day Free Trial Thru May 05, 2024!
✨
Sign Up
Login
Free Sign-up
Login
7-Day Free Trial
Home
Homepage
Membership Levels
About Us
General Discussion
Complete Stock List
The book
Membership Data Coverage
Founder's Message
Free Trial
Referral Program
Partner Program
GuruFocus Podcast
Screeners
GuruFocus Screeners
All-In-One Screener
Ben Graham Lost Formula
Canadian Faster Growers
CEO Buys
CEO Buys after Price Drop > 20%
Dividend Kings 2023
Dividend Aristocrats 2023
Dividend Growth Portfolio
Dividend Income Portfolio
Fast Growers
Good Companies
Hedge Fund Guru Top 10 Aggregated
High Quality
High Quality Low Capex w ROE ROC min
High Quality & Low Capex
High Yield Insider Buys
Historical High Dividend Yields
International Gurus' Top Holdings
James Montier Short Screen
Margin Decliners
Mega Caps
Peter Lynch & Warren Buffett
Peter Lynch Growth w Lower Valuation
Peter Lynch S&L Traded Below Book
PFCF Screener
Piotroski Score Screener
Predictable Growth Companies
Profitable predictable margin expanders
Stocks Sold w less Cash
The Stalwarts
My Screeners
Create My Screener
Value Screens
Stock Ideas
All-In-One Screener
S&P 500 Map
S&P 500 Bubble
S&P 500 Aggregate
Buffett-Munger Screener
Industry Overview
Undervalued Predictable
Benjamin Graham Net-Net
52-week/3Y/5Y Lows
52-week/3Y/5Y Highs
Magic Formula(Greenblatt)
Dividend Stocks
Peter Lynch Screen
S&P500 Grid
Predictable Companies
Spin Off List
Merger and Acquisition List
Historical Low P/B List
Historical Low P/S List
High Short Interest
Upcoming Special Dividends
Delisted Stocks
Model Portfolios
Performances Overview
Most Broadly Held Portfolio
Most Weighted Portfolio
Buffett-Munger Top 25
GF Score <= 100 Top 25
Top 25 Undervalued Predictable
Top 25 52-week Low Predictable
Top 25 Historical Low P/S
Stock Comparison
Airline Stocks
Artificial Intelligence Stocks
Bank Stocks
Biotech Stocks
Blockchain Stocks
Chinese Stocks
Dividend Stocks
EV Stocks
Growth Stocks
Oil Stocks
Value Stocks
Virtual Reality Stocks
Compare More Stocks…
Gurus
Guru Trades
Latest Guru Picks
Real Time Picks
Guru Portfolio
Score Board
Mutual Funds
Top 10 Holdings
Sector Picks
International Picks
Aggregated Portfolio
Consensus Picks
Guru Bargains
Hot Picks
Download Guru Portfolios
Industry Trends
Geographic Trend
ETFs
Options Holdings
European Shorting
Guru Lists
Complete Guru List
Warren Buffett
Bill Gates
Mohnish Pabrai
Carl Icahn
George Soros
David Tepper
Seth Klarman
Bill Ackman
Joel Greenblatt
Charlie Munger
Michael Price
Julian Robertson
Chuck Akre
David Einhorn
Tom Gayner
My Guru Lists
Insiders
Insider Trading Tracker
Real-Time Insider Picks
CEO Buys/Sells
CFO Buys/Sells
Insider Trends
Insider Cluster
Guru + Insider Double Buys
Triple Buys/Sells
Chinese Insider
German Insider
Complete Insider List
Politician Trading Tracker
Real-Time Politician Picks
Complete Politician List
Nancy Pelosi
Mitch Mcconnell
Tommy Tuberville
Josh Gottheimer
Kevin Hern
Thomas R. Carper
Susie Lee
Lois Frankel
Market
US Market Valuation
Buffett Indicator
U.S. Treasury Yield Curve
U.S. Inflation Rate
Presidential Cycle and Stock Market
Shiller P/E
Shiller P/E by Sectors
GF Value for S&P 500 Index
Fed Net Liquidity
Buffett Assets Allocation
Latest IPOs
Global Market Valuation
Global Market Overview
USA
China
Japan
India
Canada
UK
France
Germany
Brazil
Australia
More...
Economic Indicators
Economic Indicators Overview
The Dow Jones Industrial Average (DJIA)
SP 500 Index
Nasdaq Composite Index
Gross Domestic Product (GDP)
Shiller PE
Ratio of Wilshire 5000 over GNP
Civilian Unemployment Rate
Russell 2000 Index
CBOE Volatility Index (VIX)
Total Nonfarm Payrolls: All Employees
More...
Sector & Industry Performance
Global Industry Overview
USA
Asia
Europe
Canada
UK/Ireland
Oceania
Latin America
Africa
India/Pakistan
Articles
Articles
Editors' Picks
Stock Market News
Q&A with Gurus
Guru Stock Picks
Insider Transaction
Earning Reports
CEO Shareholder Letters
Podcast
Earnings Call Transcripts
Software Stock News
Biotechnology Stock News
Hardware Stock News
Banks Stock News
Metals & Mining Stock News
Drug Manufacturers Stock News
All Articles
Submit Articles
Submit Article Online
Contributor Guidelines
Tools
Model Portfolios
All-In-One Screener
Data Batch Download
Guru Portfolio Download
Insider Data Download
Excel Add-In
Google Sheets Add-On
API
Manual of Stocks
DCF Calculator
WACC Calculator
Interactive Chart
Maps
Fund Letters Archive
Stock Comparison Table
Mobile App
Discussion Board
GuruGPT
Financial Calendar
Embed Widgets
Stock Market Holidays
Discussion
Discussion Board
GuruFocus Discord
ETF
Data
Pricing
Tutorials
Tutorials
Financial Glossary
FAQ
Change Log
Contact Us
Support
Chat Support
Create a ticket
Book Demo
User Engagement Meeting
469-248-6885
Status
Take Survey
Ask the community in Discord
Subscribe
Free Trial
Group Subscription
Refer a Friend and Earn One Month of Free Membership
GURUFOCUS.COM
STOCK LIST
Healthcare
Biotechnology
Clovis Oncology Inc (OTCPK:CLVSQ)
News
Clovis Oncology Inc
1
1
OTCPK
:CLVSQ (USA)
(Delisted) $ 0.02
0 (0%)
03:49 PM EST
P/E:
At Loss
P/B:
0
Market Cap:
$ 2.17M
Enterprise V:
$ 624.47M
Volume:
-
Avg Vol (2M):
-
Warning! GuruFocus detected issues with CLVSQ.
Try a 7-Day Free Trial
to check it out.
Also Trade In:
Volume:
-
Market Cap $:
2.17M
PE Ratio:
At Loss
Avg Vol (2M):
-
Enterprise Value $:
624.47M
PB Ratio:
0
Alerts
Website
SEC Filings
Stock PDF
Dataset
Financial Download
Manual of Stocks™
Compare
0
Summary
30-Y Financials
DCF
Dividend
Guru Trades
Insider
Interactive Chart
Filings
Transcripts
News
Compare
Stock PDF
Ownership
Operating
Checklist
Vote
Definitions
Clovis Oncology Inc (OTCPK:CLVSQ) Stock News, Headlines & Updates
Clovis Oncology Inc Stock News from GuruFocus
Total 45
1
2
Aug 30, 2021
Biotech Takeovers Moved at Snail's Pace in 2nd Quarter
Barry Cohen
•
4:58pm
Jul 21, 2021
Clovis Oncology to Announce Second Quarter 2021 Financial Results and Host Webcast Conference Call on August 4
Business Wire
•
8:00am
Jul 12, 2021
Clovis Oncology Appoints Dr. Ronit Simantov to its Board of Directors
Business Wire
•
4:00pm
Jun 28, 2021
Initial Clinical Experience of FAP-2286 in Independent Named Patient Use Published in The Journal of Nuclear Medicine
Business Wire
•
7:00am
Jun 23, 2021
Clovis Oncology Announces LuMIERE Clinical Trial Evaluating Novel Peptide-Targeted Radionuclide Therapy FAP-2286 Now Open for Enrollment
Business Wire
•
7:00am
Jun 10, 2021
Clovis Oncology Announces Partial Adjournment of Annual Meeting of Stockholders
Business Wire
•
4:00pm
May 19, 2021
Clovis Oncology Highlights Rubraca® (rucaparib) and Lucitanib Data at 2021 ASCO Annual Meeting
Business Wire
•
6:00pm
May 17, 2021
Clovis Oncology Announces At-The-Market Equity Offering Program
Business Wire
•
4:00pm
May 05, 2021
Clovis Oncology Announces First Quarter 2021 Operating Results
Business Wire
•
8:00am
Apr 28, 2021
Clovis Oncology to Present at the Bank of America 2021 Health Care Conference
Business Wire
•
4:00pm
Apr 21, 2021
Clovis Oncology to Announce First Quarter 2021 Financial Results and Host Webcast Conference Call on May 5
Business Wire
•
4:00pm
Apr 18, 2021
Clovis Oncology Stock Is Believed To Be Possible Value Trap
GF Value
•
4:12am
Feb 17, 2021
Clovis Oncology to Announce Fourth Quarter and Year-End 2020 Financial Results and Host Webcast Conference Call on February 23
Business Wire
•
11:01am
Feb 11, 2021
Clovis Oncology Presents Data in Advanced Prostate Cancer at ASCO 2021 Genitourinary Cancers Symposium Virtual Meeting
Business Wire
•
11:00am
Feb 04, 2021
Clovis Oncology to Highlight Data at ASCO 2021 Genitourinary Cancers Symposium Virtual Meeting
Business Wire
•
11:02am
Dec 29, 2020
Clovis Oncology Submits Investigational New Drug Applications for Novel Peptide-Targeted Radionuclide FAP-2286 for Therapeutic and Imaging Clinical Trial
Business Wire
•
10:59am
Dec 21, 2020
Clovis Oncology's Rubraca® (rucaparib) Met the Primary Endpoint of Significantly Improving Progression-Free Survival vs. Chemotherapy in the ARIEL4 Randomized Phase 3 Treatment Study in Later-line Ovarian Cancer Patients with a BRCA mutation
Business Wire
•
11:00am
Nov 25, 2020
Clovis Oncology Announces Exercise by Existing Holder of Option to Purchase an Additional $7.5 Million Aggregate Principal Amount of the Company's 4.50% Convertible Senior Notes Due 2024
Business Wire
•
7:00pm
Nov 20, 2020
Clovis Oncology to Present at the Piper Sandler 32nd Annual Healthcare Conference
Business Wire
•
11:00am
Nov 05, 2020
Clovis Oncology Announces Debt Exchange Transaction and Offering of Convertible Senior Notes
Business Wire
•
11:00am
Oct 21, 2020
Clovis Oncology to Announce Third Quarter 2020 Financial Results and Host Webcast Conference Call on November 5
Business Wire
•
7:01pm
Sep 17, 2020
New Data Presented at ESMO Virtual Congress 2020 Highlight Breadth and Potential of Clovis Oncology Products and Pipeline
Business Wire
•
3:00am
Sep 10, 2020
Clovis Oncology Announces Oral Plenary Session Presentation at International Gynecologic Cancer Society (IGCS) Digital Annual Global Meeting
Business Wire
•
11:00am
Sep 09, 2020
Clovis Oncology to Highlight Data for its Three Portfolio Compounds at the ESMO Virtual Congress 2020
Business Wire
•
11:01am
Clovis Oncology to Present at the H.C. Wainwright 22nd Annual Global Investment Conference
Business Wire
•
7:00pm
Aug 27, 2020
FDA Approves FoundationOne® Liquid CDx to Serve as Rubraca® (rucaparib) Companion Diagnostic to Identify Eligible Patients with BRCA1/2-Mutant, Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Business Wire
•
7:00pm
Aug 05, 2020
Clovis Oncology Announces First Patient Enrolled in the Phase 2 Portion of the LIO-1 Trial Evaluating the Combination of Lucitanib and Opdivo in Gynecologic Cancers
Business Wire
•
11:00am
Jul 23, 2020
Clovis Oncology to Announce Second Quarter 2020 Financial Results and Host Webcast Conference Call on August 6
Business Wire
•
11:01am
Jun 17, 2020
Clovis Oncology to Highlight Rubraca® (rucaparib) and Lucitanib Non-Clinical Data at the AACR Virtual Annual Meeting II 2020
Business Wire
•
11:00am
Jun 11, 2020
Clovis Oncology Announces Completion of Target Enrollment in the ATHENA Trial, a Phase 3 Maintenance Treatment Study in Front-line, Newly-Diagnosed Advanced Ovarian Cancer
Business Wire
•
7:00pm
May 28, 2020
Clovis Oncology Announces New Recommendations for Rubraca® (rucaparib) Tablets in Updated National Comprehensive Cancer Network (NCCN) Guidelines® for the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Business Wire
•
11:02am
May 22, 2020
Clovis Oncology Announces Presentations at 2020 ASCO Virtual Scientific Program
Business Wire
•
7:02pm
May 21, 2020
Clovis Oncology Needs a Savior
Barry Cohen
•
12:24pm
May 19, 2020
Clovis Oncology Announces Pricing of Public Offering of Common Stock
Business Wire
•
11:00pm
May 15, 2020
Rubraca® (Rucaparib) Approved in the U.S. as Monotherapy Treatment for Patients with BRCA1/2-Mutant, Metastatic Castration-Resistant Prostate Cancer (mCRPC) Who Have Been Treated with Androgen Receptor-Directed Therapy and a Taxane-Based Chemotherapy
Business Wire
•
3:00pm
May 06, 2020
Clovis Oncology Announces First Quarter 2020 Operating Results
Business Wire
•
7:00pm
Apr 30, 2020
Clovis Oncology to Present at the Bank of America Health Care Conference 2020
Business Wire
•
7:00pm
Apr 22, 2020
Clovis Oncology to Announce First Quarter 2020 Financial Results and Host Webcast Conference Call on May 5
Business Wire
•
7:00pm
Apr 15, 2020
Clovis Oncology Announces Debt Exchange Transaction
Business Wire
•
7:00pm
Dec 02, 2019
Thinking about buying stock in Aurora Cannabis, Advanced Micro Devices, Clovis Oncology, Facebook, or AT&T?
PRNewswire
•
11:02am
Total 45
1
2
Show
20
40
60
80
100
No data
Entries
Headlines
Total 0
1
No recent news